株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

胃癌:パイプライン製品の分析

Gastric Cancer - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 232773
出版日 ページ情報 英文 982 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.05円で換算しております。
Back to Top
胃癌:パイプライン製品の分析 Gastric Cancer - Pipeline Review, H1 2017
出版日: 2017年05月16日 ページ情報: 英文 982 Pages
概要

胃癌は、胃の内膜に発生する悪性腫瘍で、その兆候と症状には、倦怠感、腹痛、嘔吐、体重の減少、食後の膨満感、胸やけ、消化不良などがあります。胃癌を罹患する原因としては、喫煙、2悪性貧血、胃のポリープ、ピロリ菌への感染、胃癌を発症しやすい家系などが挙げられます。

当レポートでは、胃癌治療薬におけるパイプライン製品の概要や治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

胃癌 - 概要

胃癌 - 治療薬の開発

胃癌 - 治療薬の評価

胃癌の治療薬開発に従事している企業

薬剤プロファイル

胃癌 - 休止中のプロジェクト

胃癌 - 開発が中止された製品

胃癌 - 製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9280IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H1 2017, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 14, 70, 77, 7, 74, 12 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 4, 8 and 1 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Gastric Cancer - Overview
  • Gastric Cancer - Therapeutics Development
  • Gastric Cancer - Therapeutics Assessment
  • Gastric Cancer - Companies Involved in Therapeutics Development
  • Gastric Cancer - Drug Profiles
  • Gastric Cancer - Dormant Projects
  • Gastric Cancer - Discontinued Products
  • Gastric Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Gastric Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Gastric Cancer - Pipeline by 3SBio Inc, H1 2017
  • Gastric Cancer - Pipeline by AB Science SA, H1 2017
  • Gastric Cancer - Pipeline by AbbVie Inc, H1 2017
  • Gastric Cancer - Pipeline by AbGenomics International Inc, H1 2017
  • Gastric Cancer - Pipeline by Abion Inc, H1 2017
  • Gastric Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
  • Gastric Cancer - Pipeline by ADC Therapeutics Sarl, H1 2017
  • Gastric Cancer - Pipeline by Aduro BioTech Inc, H1 2017
  • Gastric Cancer - Pipeline by Advaxis Inc, H1 2017
  • Gastric Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Gastric Cancer - Pipeline by Agenus Inc, H1 2017
  • Gastric Cancer - Pipeline by Almac Discovery Ltd, H1 2017
  • Gastric Cancer - Pipeline by Alteogen Inc, H1 2017
  • Gastric Cancer - Pipeline by Ambrx Inc, H1 2017
  • Gastric Cancer - Pipeline by amcure GmbH, H1 2017
  • Gastric Cancer - Pipeline by Amgen Inc, H1 2017
  • Gastric Cancer - Pipeline by ANP Technologies Inc, H1 2017
  • Gastric Cancer - Pipeline by Antikor Biopharma Ltd, H1 2017
  • Gastric Cancer - Pipeline by arGEN-X BV, H1 2017
  • Gastric Cancer - Pipeline by Array BioPharma Inc, H1 2017
  • Gastric Cancer - Pipeline by Asana BioSciences LLC, H1 2017
  • Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017
  • Gastric Cancer - Pipeline by Astellas Pharma Inc, H1 2017
  • Gastric Cancer - Pipeline by AstraZeneca Plc, H1 2017
  • Gastric Cancer - Pipeline by Athenex Inc, H1 2017
  • Gastric Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2017
  • Gastric Cancer - Pipeline by Bayer AG, H1 2017
  • Gastric Cancer - Pipeline by BeiGene Ltd, H1 2017
  • Gastric Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2017
  • Gastric Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017
  • Gastric Cancer - Pipeline by Bionovis SA, H1 2017
  • Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Gastric Cancer - Pipeline by Boston Biomedical Inc, H1 2017
  • Gastric Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Gastric Cancer - Pipeline by Camel-IDS NV, H1 2017
  • Gastric Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017
  • Gastric Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
  • Gastric Cancer - Pipeline by Celgene Corp, H1 2017
  • Gastric Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017
  • Gastric Cancer - Pipeline by Cellectar Biosciences Inc, H1 2017
  • Gastric Cancer - Pipeline by Celltrion Inc, H1 2017
  • Gastric Cancer - Pipeline by Celon Pharma SA, H1 2017
  • Gastric Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2017
  • Gastric Cancer - Pipeline by Curaxys SL, H1 2017
  • Gastric Cancer - Pipeline by Cytori Therapeutics Inc, H1 2017
  • Gastric Cancer - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Gastric Cancer - Pipeline by Debiopharm International SA, H1 2017
  • Gastric Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
  • Gastric Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017
  • Gastric Cancer - Pipeline by Eli Lilly and Company, H1 2017
  • Gastric Cancer - Pipeline by EOS Biosciences Inc, H1 2017
  • Gastric Cancer - Pipeline by Erytech Pharma SA, H1 2017
  • Gastric Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
  • Gastric Cancer - Pipeline by Exelixis Inc, H1 2017
  • Gastric Cancer - Pipeline by F-star Biotechnology Ltd, H1 2017
  • Gastric Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Gastric Cancer - Pipeline by Five Prime Therapeutics Inc, H1 2017
  • Gastric Cancer - Pipeline by Frost Biologic Inc, H1 2017
  • Gastric Cancer - Pipeline by Galena Biopharma Inc, H1 2017
  • Gastric Cancer - Pipeline by Genelux Corp, H1 2017
  • Gastric Cancer - Pipeline by Genentech Inc, H1 2017
  • Gastric Cancer - Pipeline by Gilead Sciences Inc, H1 2017
  • Gastric Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Gastric Cancer - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
  • Gastric Cancer - Pipeline by GlycoNex Inc, H1 2017
  • Gastric Cancer - Pipeline by Glycotope GmbH, H1 2017
  • Gastric Cancer - Pipeline by Green Cross Corp, H1 2017
  • Gastric Cancer - Pipeline by Halozyme Therapeutics Inc, H1 2017
  • Gastric Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Gastric Cancer - Pipeline by Horizon Pharma Plc, H1 2017
  • Gastric Cancer - Pipeline by Hutchison China MediTech Ltd, H1 2017
  • Gastric Cancer - Pipeline by Ignyta Inc, H1 2017
  • Gastric Cancer - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017
  • Gastric Cancer - Pipeline by Immunomedics Inc, H1 2017
  • Gastric Cancer - Pipeline by Incyte Corp, H1 2017
  • Gastric Cancer - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Gastric Cancer - Pipeline by Inspyr Therapeutics Inc, H1 2017
  • Gastric Cancer - Pipeline by Insys Therapeutics Inc, H1 2017
  • Gastric Cancer - Pipeline by Intezyne Technologies Inc, H1 2017
  • Gastric Cancer - Pipeline by Ipsen SA, H1 2017
  • Gastric Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
  • Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017
  • Gastric Cancer - Pipeline by Johnson & Johnson, H1 2017
  • Gastric Cancer - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
  • Gastric Cancer - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2017
  • Gastric Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
  • Gastric Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017
  • Gastric Cancer - Pipeline by LegoChem Biosciences Inc, H1 2017
  • Gastric Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2017
  • Gastric Cancer - Pipeline by MacroGenics Inc, H1 2017
  • Gastric Cancer - Pipeline by MaxiVAX SA, H1 2017
  • Gastric Cancer - Pipeline by Mebiopharm Co Ltd, H1 2017
  • Gastric Cancer - Pipeline by MedImmune LLC, H1 2017
  • Gastric Cancer - Pipeline by Merck & Co Inc, H1 2017
  • Gastric Cancer - Pipeline by Merck KGaA, H1 2017
  • Gastric Cancer - Pipeline by Mersana Therapeutics Inc, H1 2017
  • Gastric Cancer - Pipeline by Merus NV, H1 2017
  • Gastric Cancer - Pipeline by Mirati Therapeutics Inc, H1 2017
  • Gastric Cancer - Pipeline by Molecular Partners AG, H1 2017
  • Gastric Cancer - Pipeline by Molecular Targeting Technologies Inc, H1 2017
  • Gastric Cancer - Pipeline by MolMed SpA, H1 2017
  • Gastric Cancer - Pipeline by NanoCarrier Co Ltd, H1 2017
  • Gastric Cancer - Pipeline by Novartis AG, H1 2017
  • Gastric Cancer - Pipeline by Novogen Ltd, H1 2017
  • Gastric Cancer - Pipeline by OBI Pharma Inc, H1 2017
  • Gastric Cancer - Pipeline by Oncobiologics Inc, H1 2017
  • Gastric Cancer - Pipeline by Oncolys BioPharma Inc, H1 2017
  • Gastric Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H1 2017
  • Gastric Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Gastric Cancer - Pipeline by Opsona Therapeutics Ltd, H1 2017
  • Gastric Cancer - Pipeline by Panacea Biotec Ltd, H1 2017
  • Gastric Cancer - Pipeline by Patrys Ltd, H1 2017
  • Gastric Cancer - Pipeline by Pfizer Inc, H1 2017
  • Gastric Cancer - Pipeline by Pharma Mar SA, H1 2017
  • Gastric Cancer - Pipeline by Plexxikon Inc, H1 2017
  • Gastric Cancer - Pipeline by Puma Biotechnology Inc, H1 2017
  • Gastric Cancer - Pipeline by Redx Pharma Plc, H1 2017
  • Gastric Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
  • Gastric Cancer - Pipeline by Rgenix Inc, H1 2017
  • Gastric Cancer - Pipeline by Rhizen Pharmaceuticals SA, H1 2017
  • Gastric Cancer - Pipeline by Richter Gedeon Nyrt, H1 2017
  • Gastric Cancer - Pipeline by Samumed LLC, H1 2017
  • Gastric Cancer - Pipeline by Sanofi, H1 2017
  • Gastric Cancer - Pipeline by Selecta Biosciences Inc, H1 2017
  • Gastric Cancer - Pipeline by Sequella Inc, H1 2017
  • Gastric Cancer - Pipeline by Shionogi & Co Ltd, H1 2017
  • Gastric Cancer - Pipeline by Simcere Pharmaceutical Group, H1 2017
  • Gastric Cancer - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Gastric Cancer - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
  • Gastric Cancer - Pipeline by Stelic Institute & Co Inc, H1 2017
  • Gastric Cancer - Pipeline by Supratek Pharma Inc, H1 2017
  • Gastric Cancer - Pipeline by SynCore Biotechnology Co Ltd, H1 2017
  • Gastric Cancer - Pipeline by Synovo GmbH, H1 2017
  • Gastric Cancer - Pipeline by Synthon Holdings BV, H1 2017
  • Gastric Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
  • Gastric Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2017
  • Gastric Cancer - Pipeline by Takis Srl, H1 2017
  • Gastric Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H1 2017
  • Gastric Cancer - Pipeline by Transgene SA, H1 2017
  • Gastric Cancer - Pipeline by United BioPharma Inc, H1 2017
  • Gastric Cancer - Pipeline by Vaxon Biotech, H1 2017
  • Gastric Cancer - Pipeline by Viracta Therapeutics Inc, H1 2017
  • Gastric Cancer - Pipeline by XuanZhu Pharma Co Ltd, H1 2017
  • Gastric Cancer - Pipeline by Zymeworks Inc, H1 2017
  • Gastric Cancer - Dormant Projects, H1 2017
  • Gastric Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Gastric Cancer - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Gastric Cancer - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Gastric Cancer - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Gastric Cancer - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Gastric Cancer - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Gastric Cancer - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Gastric Cancer - Discontinued Products, H1 2017
  • Gastric Cancer - Discontinued Products, H1 2017 (Contd..1), H1 2017
  • Gastric Cancer - Discontinued Products, H1 2017 (Contd..2), H1 2017

List of Figures

  • Number of Products under Development for Gastric Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top